Head-To-Head Contrast: Ampio Pharmaceuticals (NYSE:AMPE) vs. Trevena (NASDAQ:TRVN)

Institutional & Insider Ownership

5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.6% of Trevena shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Comparatively, 2.7% of Trevena shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Ampio Pharmaceuticals and Trevena”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63 million	($11.01)	-0.02
Trevena	$443,000.00	0.00	-$40.29 million	($47.04)	0.00

Ampio Pharmaceuticals has higher earnings, but lower revenue than Trevena. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Ampio Pharmaceuticals has a beta of 5.57, indicating that its share price is 457% more volatile than the S&P 500. Comparatively, Trevena has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.

Profitability

This table compares Ampio Pharmaceuticals and Trevena’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
Trevena	N/A	N/A	-119.55%

Summary

Ampio Pharmaceuticals beats Trevena on 5 of the 8 factors compared between the two stocks.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

About Trevena

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.